E6/E7 viral messenger RNA (mRNA) refers to the genetic instructions produced by high-risk strains of human papillomavirus (HPV) that drive cells toward cancer. When HPV infects cells, it can produce these specific mRNA molecules, which tell the cell to build two proteins, E6 and E7, that disable the body’s natural tumor-suppression defenses. Detecting this mRNA has become a meaningful tool in cervical cancer screening because its presence signals that the virus isn’t just sitting quietly in your cells but is actively doing damage.
How E6 and E7 Proteins Cause Harm
Your cells have built-in safeguards against cancer. Two of the most important are a protein called p53, which triggers damaged cells to self-destruct before they become dangerous, and a protein called pRb, which acts as a brake on cell division. The E6 and E7 proteins produced from this mRNA specifically target and destroy both safeguards.
The E6 protein hijacks a cellular recycling system to tag p53 for destruction. Once p53 is gone, damaged cells that should die instead survive and accumulate further genetic errors. Meanwhile, the E7 protein binds to pRb and sends it to the same recycling pathway, removing the brake on cell division. With both safeguards knocked out, infected cells divide uncontrollably, which is the foundation of cancer development.
E6 and E7 are the only viral genes that are always retained and expressed in HPV-positive cancer cells. Other parts of the virus can be lost or silenced over time, but these two genes persist because the cancer depends on them to maintain its growth.
Why the Virus Starts Overproducing This mRNA
In the early stages of an HPV infection, the virus exists as a small circular loop of DNA floating freely inside the cell’s nucleus. During this phase, another viral gene called E2 acts as a supervisor, keeping E6 and E7 expression low. Most HPV infections stay in this controlled state and are eventually cleared by the immune system without ever causing problems.
The danger increases when the virus integrates its DNA into the host cell’s own chromosomes. This integration typically breaks the viral DNA right at the E2 gene, destroying the supervisor. Without E2 holding them in check, E6 and E7 mRNA production ramps up dramatically. This overexpression is the key event that pushes an infection from harmless toward precancerous changes and, eventually, cervical cancer.
What E6/E7 mRNA Testing Tells You
Standard HPV tests look for the virus’s DNA, which tells you whether the virus is present in your cells. E6/E7 mRNA testing goes a step further: it tells you whether the virus is transcriptionally active, meaning it’s actually producing the cancer-driving instructions. You can carry HPV DNA without it doing anything harmful. But if E6/E7 mRNA is present, the virus is actively working to disable your cells’ defenses.
This distinction has real clinical value. In one study, E6/E7 mRNA transcripts were detected in 25% of women with normal biopsy findings, 32% of those with mild precancerous changes (CIN1), 44% with moderate changes (CIN2), and 100% of those with severe precancerous lesions (CIN3). That steep climb shows a clear correlation between mRNA activity and the severity of disease. mRNA testing also showed higher specificity for high-grade lesions than DNA testing (72.7% versus 56.2%) and a higher positive predictive value (59.3% versus 49.0%), meaning a positive mRNA result is more likely to correspond to a lesion that actually needs treatment.
The detection of E6/E7 mRNA in some women with normal-appearing cells is also telling. It suggests the virus can be oncogenically active before it produces visible cellular changes, making mRNA a potentially earlier warning signal than what a Pap smear alone would catch.
How the Test Works in Practice
The most widely used mRNA-based screening tool is the Aptima HPV assay, which detects E6/E7 mRNA from 14 high-risk HPV types, including HPV-16 and HPV-18, the two strains responsible for most cervical cancers. The test works by amplifying any E6/E7 mRNA present in a cervical sample. Results are interpreted automatically based on the copy number of mRNA molecules compared against a clinical threshold. If any of the 14 targeted types are producing E6/E7 mRNA, the result is positive.
Current U.S. management guidelines from the American Society for Colposcopy and Cervical Pathology (ASCCP) recognize both HPV DNA and HPV mRNA assays as approved options for screening. However, the risk estimates underlying the 2019 guidelines were originally developed using DNA-based testing data. For mRNA-based tests that don’t have standalone primary screening approval, guidelines recommend using them alongside a Pap smear (cotesting) rather than as a sole screening method.
mRNA Testing Versus DNA Testing
The practical difference between the two approaches comes down to what you’re trying to learn. DNA testing is highly sensitive: it catches nearly all HPV infections, including many that will clear on their own without ever causing harm. This means more positive results but also more follow-up procedures for infections that were never going to become cancer.
mRNA testing trades a small amount of that sensitivity for better specificity. Because it only flags infections where the virus is actively expressing its cancer-causing genes, it reduces unnecessary follow-up. In a large prospective study comparing the two methods, mRNA-based testing was more specific, meaning it was better at correctly identifying women who did not have clinically significant disease. For the individual being screened, this can mean fewer colposcopies and biopsies for infections that pose no real threat.
Both testing methods have strong negative predictive values, meaning a negative result on either test reliably indicates you do not have a high-grade cervical lesion. The choice between DNA and mRNA testing often depends on what your healthcare provider is trying to determine: whether the virus is present at all, or whether it’s actively progressing toward disease.